Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 11 de 11
Filtre
1.
Arq. bras. neurocir ; 40(3): 253-256, 15/09/2021.
Article Dans Anglais | LILACS | ID: biblio-1362147

Résumé

Tumor heterogeneity is the concept that different tumor cells provide distinct biomorphological lesions, gene expressions, proliferation, microenvironment and graduated capacity of metastatic lesions. Brain tumor heterogeneity has been recently discussed about the interesting interaction of chronic inflammation, microenvironment, epigenetics and glioma steam cells. Brain tumors remain a challenge with regards to medication and disease, due to the lack of treatment options and unsatisfactory results. These results might be the result of the brain tumor heterogeneity and its multiple resistance mechanisms to chemo and radiotherapy.


Sujets)
Cellules souches tumorales/cytologie , Tumeurs du cerveau/génétique , Hétérogénéité génétique , Analyse de profil d'expression de gènes , Gliome/génétique , Récepteurs à activité tyrosine kinase/génétique , Résistance aux médicaments antinéoplasiques/génétique , Niche de cellules souches/génétique , Microenvironnement tumoral , Évolution clonale/génétique , Microenvironnement cellulaire/génétique , RNA-Seq
2.
Int. braz. j. urol ; 42(4): 817-824, July-Aug. 2016. tab, graf
Article Dans Anglais | LILACS | ID: lil-794669

Résumé

ABSTRACT Purpose: In a previous study the vaccine was effective against bladder cancer in a mouse model. However, a small portion of tumors regrew because the vaccine could not eliminate bladder cancer stem cells (CSCs). In this study, we showed a modified method for the isolation of bladder CSCs using a combination of differential adhesion method and serum-free culture medium (SFM) method. Materials and Methods: Trypsin-resistant cells and trypsin-sensitive cells were isolated from MB49, EJ and 5637 cells by a combination of differential adhesion method and SFM method. The CSCs characterizations of trypsin-resistant cells were verified by the flow cytometry, the western blotting, the quantitative polymerase chain reaction, the resistance to chemotherapy assay, the transwell assay, and the tumor xenograft formation assay. Results: Trypsin-resistant cells were isolated and identified in CSCs characters, with high expression of CSCs markers, higher resistance to chemotherapy, greater migration in vitro, and stronger tumorigenicity in vivo. Conclusion: Trypsin-resistant cells displayed specific CSCs properties. Our study showed trypsin-resistant cells were isolated successfully with a modified method using a combination of differential adhesion method and SFM method.


Sujets)
Animaux , Souris , Cellules souches tumorales/cytologie , Tumeurs de la vessie urinaire/anatomopathologie , Trypsine/pharmacologie , Adhérence cellulaire/effets des médicaments et des substances chimiques , Séparation cellulaire/méthodes , Techniques de culture cellulaire/méthodes , Cellules souches tumorales/composition chimique , Marqueurs biologiques tumoraux , Différenciation cellulaire , Milieux de culture sans sérum , Vaccins anticancéreux/immunologie , Lignée cellulaire tumorale , Réaction de polymérisation en chaine en temps réel , Cytométrie en flux , Souris nude
3.
Journal of Korean Medical Science ; : 360-370, 2016.
Article Dans Anglais | WPRIM | ID: wpr-95370

Résumé

Cancer stem cells (CSCs) have tumor initiation, self-renewal, metastasis and chemo-resistance properties in various tumors including colorectal cancer. Targeting of CSCs may be essential to prevent relapse of tumors after chemotherapy. Phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signals are central regulators of cell growth, proliferation, differentiation, and apoptosis. These pathways are related to colorectal tumorigenesis. This study focused on PI3K and mTOR pathways by inhibition which initiate differentiation of SW620 derived CSCs and investigated its effect on tumor progression. By using rapamycin, LY294002, and NVP-BEZ235, respectively, PI3K and mTOR signals were blocked independently or dually in colorectal CSCs. Colorectal CSCs gained their differentiation property and lost their stemness properties most significantly in dual-blocked CSCs. After treated with anti-cancer drug (paclitaxel) on the differentiated CSCs cell viability, self-renewal ability and differentiation status were analyzed. As a result dual-blocking group has most enhanced sensitivity for anti-cancer drug. Xenograft tumorigenesis assay by using immunodeficiency mice also shows that dual-inhibited group more effectively increased drug sensitivity and suppressed tumor growth compared to single-inhibited groups. Therefore it could have potent anti-cancer effects that dual-blocking of PI3K and mTOR induces differentiation and improves chemotherapeutic effects on SW620 human colorectal CSCs.


Sujets)
Animaux , Humains , Mâle , Souris , Antigène AC133/génétique , Antinéoplasiques/pharmacologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Survie cellulaire/effets des médicaments et des substances chimiques , 4H-1-Benzopyran-4-ones/pharmacologie , Tumeurs colorectales/traitement médicamenteux , Imidazoles/pharmacologie , Souris de lignée BALB C , Souris nude , Morpholines/pharmacologie , Cellules souches tumorales/cytologie , Paclitaxel/pharmacologie , Phosphatidylinositol 3-kinases/antagonistes et inhibiteurs , Quinoléines/pharmacologie , Facteurs de transcription SOX-B1/génétique , Transduction du signal/effets des médicaments et des substances chimiques , Sirolimus/pharmacologie , Sérine-thréonine kinases TOR/antagonistes et inhibiteurs , Tests d'activité antitumorale sur modèle de xénogreffe
4.
Braz. j. med. biol. res ; 47(6): 478-482, 06/2014. graf
Article Dans Anglais | LILACS | ID: lil-709446

Résumé

Accumulating evidence has indicated the importance of cancer stem cells in carcinogenesis. The goal of the present study was to determine the effect of low-dose cisplatin on enriched liver cancer stem cells (LCSCs). Human hepatoblastoma HepG2 cells were treated with concentrations of cisplatin ranging from 1 to 5 μg/mL. Cell survival and proliferation were evaluated using a tetrazolium dye (MTT) assay. LCSCs were identified using specific markers, namely aldehyde dehydrogenase-1 (ALDH1) and CD133. The percentage of ALDH1+ or CD133+ cells was examined by flow cytometric analysis. The expression of ALDH1 and/or CD133 in HepG2 cells was determined by immunocytochemical analysis. Low-dose cisplatin treatment significantly decreased cell survival in HepG2 cells after 24 or 72 h. However, the percentage of LCSCs in the surviving cells was greatly increased. The percentage of ALDH1+ or CD133+ cells was increased in a time- and dose-dependent manner after treatment with 1-4 μg/mL cisplatin, whereas 5 μg/mL cisplatin exposure slightly reduced the number of positive cells. These findings indicate that low-dose cisplatin treatment may efficiently enrich the LCSC population in HepG2 cells.


Sujets)
Humains , Antinéoplasiques/administration et posologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cisplatine/administration et posologie , Hépatoblastome/traitement médicamenteux , Tumeurs du foie/traitement médicamenteux , Cellules souches tumorales/effets des médicaments et des substances chimiques , Antigènes CD/analyse , Lignée cellulaire tumorale , Carcinogenèse/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Cisplatine/usage thérapeutique , Cytométrie en flux , Glycoprotéines/analyse , Hépatoblastome/anatomopathologie , Immunohistochimie , Isoenzymes/analyse , Tumeurs du foie/anatomopathologie , Cellules souches tumorales/cytologie , Peptides/analyse , Retinal dehydrogenase/analyse , Sels de tétrazolium , Marqueurs biologiques tumoraux/analyse
5.
Pesqui. vet. bras ; 34(5): 455-461, May 2014. ilus, tab
Article Dans Portugais | LILACS | ID: lil-714717

Résumé

As células-tronco tumorais (CTTs) pertencem a uma pequena população de células dentro do tumor com propriedades de autorrenovação e diferenciação em outros tipos celulares. Neste estudo avaliou-se o comportamento tanto das porções mesenquimais quanto das epiteliais de seis carcinossarcomas (CSs), 11 carcinomas em tumores mistos (CTMs) grau I, 11 grau II e 10 grau III. Nas porções epiteliais dos CS e CTM foram observadas imunomarcações para os anticorpos CD44, CD24, Oct-4 e ALDH-1. Nas porções mesenquimais dos CS, nas porções epiteliais dos CTMs graus II e III não houve imunomarcação para o ALDH-1. Concluiu-se que as CTTs são expressas em proporções iguais tanto nas porções mesenquimais quanto nas epiteliais dos CSs e ausentes nas porções mesenquimais bem diferenciadas de CTMs.


Cancer stem cells belong to a small population of cells within the tumor with properties of self-renewal and differentiation into other cell types. In this study, the behavior of both portions, mesenchymal and epithelial, was evaluated. Six carcinosarcomas (CSs), 11 carcinomas within mixed tumors (CWMTs) grade I, 11 grade II, and 10 grade III were evaluated. In the epithelial portions of the CS and CWMTs was observed immunostaining for antibodies CD44, CD24, Oct-4 and ALDH-1. In the mesenchymal portions of the CS, in the epithelial portions of CMTs grades II and III no immunostaining for ALDH-1 was found. It was concluded that the tumor stem cells are expressed in equal proportions in the epithelial and mesenchymal portions of the CS. No immunostaining in the mesenchymal portions of well-differentiated CWMTs was seen.


Sujets)
Animaux , Femelle , Chiens , Carcinomes/médecine vétérinaire , Carcinosarcome/médecine vétérinaire , Cellules épithéliales/cytologie , Cellules souches mésenchymateuses/cytologie , Cellules souches tumorales/cytologie , Cytométrie en flux
6.
Yonsei Medical Journal ; : 92-100, 2013.
Article Dans Anglais | WPRIM | ID: wpr-66236

Résumé

PURPOSE: Cancer stem cells have recently been thought to be closely related to tumor development and reoccurrence. It may be a promising way to cure malignant glioma by using glioma stem cell-targeted dendritic cells as a tumor vaccine. In this study, we explored whether pulsing dendritic cells with antigens of glioma stem cells was a potent way to induce specific cytotoxic T lymphocytes and anti-tumor immunity. MATERIALS AND METHODS: Cancer stem cells were cultured from glioma cell line U251. Lysate of glioma stem cells was obtained by the repeated freezing and thawing method. Dendritic cells (DCs) were induced and cultured from the murine bone marrow cells, the biological characteristics were detected by electron microscope and flow cytometry. The DC vaccine was obtained by mixing DCs with lysate of glioma stem cells. The DC vaccine was charactirizated through the mixed lymphocyte responses and cell killing experiment in vitro. Level of interferon-gamma (IFN-gamma) in the supernatant was checked by ELISA. RESULTS: After stimulation of lysate of glioma stem cell, expression of surface molecules of DC was up-regulated, including CD80, CD86, CD11C and MHC-II. DCs pulsed with lysate of glioma stem cells were more effective than the control group in stimulating original glioma cells-specific cytotoxic T lymphocytes responses, killing glioma cells and boosting the secretion of IFN-gamma in vitro. CONCLUSION: The results demonstrated DCs loaded with antigens derived from glioma stem cells can effectively stimulate naive T cells to form specific cytotoxic T cells, kill glioma cells cultured in vitro.


Sujets)
Animaux , Humains , Mâle , Souris , Antigènes néoplasiques/immunologie , Apoptose , Tumeurs du cerveau/thérapie , Vaccins anticancéreux/usage thérapeutique , Lignée cellulaire tumorale , Prolifération cellulaire , Cellules dendritiques/cytologie , Test ELISA , Cytométrie en flux , Gliome/thérapie , Interféron gamma/métabolisme , Souris de lignée C57BL , Transplantation tumorale , Cellules souches tumorales/cytologie , Lymphocytes T cytotoxiques/immunologie
7.
Journal of Korean Medical Science ; : 542-549, 2013.
Article Dans Anglais | WPRIM | ID: wpr-71535

Résumé

Multiparametric flow cytometry (MFC) allows discrimination between normal and neoplastic plasma cells (NeoPCs) within the bone marrow plasma cell (BMPC) compartment. This study sought to characterize immunophenotypes and quantitate the proportion of NeoPCs in BMPCs to diagnose plasma cell myeoma (PCM) and evaluate the prognostic impact of this method. We analyzed the MFC data of the bone marrow aspirates of 76 patients with PCM and 33 patients with reactive plasmacytosis. MFC analysis was performed using three combinations: CD38/CD138/-/CD45; CD56/CD20/CD138/CD19; and CD27/CD28/CD138/CD117. The plasma cells of patients with reactive plasmacytosis demonstrated normal immunophenotypic patterns. Aberrant marker expression was observed in NeoPCs, with negative CD19 expression observed in 100% of cases, CD56+ in 73.7%, CD117+ in 15.2%, CD27- in 10.5%, CD20+ in 9.2%, and CD28+ in 1.3%. In PCM patients, more than 20% of NeoPCs/BMPCs were significantly associated with factors suggestive of poor clinical outcomes. Patients who were CD27- or CD56+/CD27-, demonstrated shorter overall survival than patients of other CD56/CD27 combinations. Our results support the clinical value of immunophenotyping and quantifying NeoPCs in PCM patients. This strategy could help to reveal poor prognostic categories and delineate surrogate markers for risk stratification in PCM patients.


Sujets)
Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen , Antigènes CD27/métabolisme , Antigènes CD56/métabolisme , Asiatiques , Cellules de la moelle osseuse/cytologie , Cytométrie en flux , Immunophénotypage , Estimation de Kaplan-Meier , Myélome multiple/métabolisme , Stadification tumorale , Cellules souches tumorales/cytologie , Pronostic , République de Corée , Facteurs de risque
8.
Article Dans Anglais | IMSEAR | ID: sea-135557

Résumé

In the recent years, knowledge about cancer biomarkers has increased tremendously providing great opportunities for improving the management of cancer patients by enhancing the efficiency of detection and efficacy of treatment. Recent technological advancement has enabled the examination of many potential biomarkers and renewed interest in developing new biomarkers. Biomarkers of cancer could include a broad range of biochemical entities, such as nucleic acids, proteins, sugars, lipids, and small metabolites, cytogenetic and cytokinetic parameters as well as whole tumour cells found in the body fluid. A comprehensive understanding of the relevance of each biomarker will be very important not only for diagnosing the disease reliably, but also help in the choice of multiple therapeutic alternatives currently available that is likely to benefit the patients. This review provides a brief account on various biomarkers for diagnosis, prognosis and therapeutic purposes, which include markers already in clinical practice as well as various upcoming biomarkers.


Sujets)
Antigènes néoplasiques/diagnostic , ADN viral/diagnostic , Épigenèse génétique/génétique , Antigènes de surface du virus de l'hépatite B/diagnostic , Humains , Tumeurs/diagnostic , Tumeurs/thérapie , Cellules tumorales circulantes , Cellules souches tumorales/cytologie , Lymphocytes T régulateurs/cytologie , Marqueurs biologiques tumoraux/génétique , Marqueurs biologiques tumoraux/métabolisme
9.
Yonsei Medical Journal ; : 622-632, 2010.
Article Dans Anglais | WPRIM | ID: wpr-46869

Résumé

MicroRNAs (miRNAs) are small non-coding RNAs that regulate messenger RNAs at the post-transcriptional level. They play an important role in the control of cell physiological functions, and their alterations have been related to cancer, where they can function as oncogenes or tumor suppressor genes. Recently, they have emerged as key regulators of "stemness", collaborating in the maintenance of pluripotency, control of self-renewal, and differen-tiation of stem cells. The miRNA pathway has been shown to be crucial in embryonic development and in embryonic stem (ES) cells, as shown by Dicer knockout analysis. Specific patterns of miRNAs have been reported to be expressed only in ES cells and in early phases of embryonic development. Moreover, many cancers present small populations of cells with stem cell characteristics, called cancer stem cells (CSCs). CSCs are responsible for relapse and treatment failure in many cancer patients, and the comparative analysis of expression patterns between ES cells and tumors can lead to the identification of a miRNA signature to define CSCs. Most of the key miRNAs identified to date in ES cells have been shown to play a role in tumor diagnosis or prognosis, and may well prove to be essential in cancer therapy in the foreseeable future.


Sujets)
Humains , Cellules souches embryonnaires/cytologie , microARN/génétique , Modèles biologiques , Cellules souches tumorales/cytologie , Transduction du signal/génétique
10.
Professional Medical Journal-Quarterly [The]. 1998; 5 (1): 35-40
Dans Anglais | IMEMR | ID: emr-49403

Résumé

This study is based on an analysis of 1000 fine needle aspiration biopsies in which both cytology smears and paraffin cell block were available. The histology slides from these cell blocks were studied and the cases were divided into 3 categories. In category A 903 [90.3%] cases fall which show a definitive histological diagnosis of the lesion as well as type of the lesion can be made. In category B, included 81 [8.1%] cases, only the presence of lesion could be detected, but the type of lesion was not ascertained. In category C which consisted of 16 [1.6%] cases, the tissue was insufficient for reliable diagnosis. Comparison of the cytologic diagnosis based on aspiration smear with the cell block diagnosis revealed that in 210 [21%] cases only cell block was positive while in another 130 [13%] of cases the diagnosis from the cell block was more precise and specific. These results indicate that cell blocks can enhance the effectiveness of fine needle aspiration biopsy in establishing a pathologic diagnosis. Moreover the cell block preparation in addition to routine FNA cytology smears provide a valuable tool for the evaluation of a lesion and for proper selection of a patient for surgery or for other means of treatment


Sujets)
Tumeurs/diagnostic , Cellules souches tumorales/cytologie , Techniques histologiques
11.
Indian J Exp Biol ; 1992 Jun; 30(6): 478-81
Article Dans Anglais | IMSEAR | ID: sea-60423

Résumé

Differential radioprotection between normal tissues and carcinoma was observed in C3H/J mice treated with a combination of 5-hydroxy L-tryptophan (5-HTP, 100 mg/kg) and 2-aminoethylisothiuronium bromide hydrobromide (AET, 20 mg/kg). Protection to normal tissues was judged by LD50(30) and by radiation induced damage to bone marrow(BM) using clonogenic ability of blood forming stem cells (10 day CFUs) as the criteria. Pretreatment with 5-HTP + AET combination 30 min before whole body gamma radiation (WBGR) enhanced the recoveries of the number of blood forming stem cells in BM of irradiated mice after 0, 7th and 10th day of irradiation. LD50(30) for C3H/J mice was 7.3 Gy and the dose modifying factor (DMF) of 5-HTP + AET combination was 1.76. On the contrary, pretreatment with this combination did not protect the mammary carcinoma transplanted in C3H/J mice, when exposed to 80 Gy soft X-rays.


Sujets)
5-Hydroxytryptophane/pharmacologie , Animaux , Moelle osseuse/effets des médicaments et des substances chimiques , Cellules de la moelle osseuse , Survie cellulaire , Association médicamenteuse , Femelle , Rayons gamma , Mâle , Tumeurs expérimentales de la mamelle , Souris , Souris de lignée C3H , Cellules souches tumorales/cytologie , Radioprotecteurs/pharmacologie , bêta-Aminoéthyl-isothiourée/pharmacologie
SÉLECTION CITATIONS
Détails de la recherche